Akzo Nobel India Limited (NSE:AKZOINDIA)

Intercept Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	4,295	4,266	3,351	2,901	2,076
Depreciation & Amortization	894	823	825	759	755
Loss (Gain) From Sale of Assets	7	11	11	20	26
Loss (Gain) From Sale of Investments	-11	-	-	-7	-
Provision & Write-off of Bad Debts	31	40	23	-21	-7
Other Operating Activities	-411	-489	-344	-754	-227
Change in Accounts Receivable	-1,258	-269	-601	-799	-166
Change in Inventory	-759	-201	572	-1,681	-641
Change in Accounts Payable	94	1,443	272	697	1,228
Change in Other Net Operating Assets	228	-769	753	99	-212
Operating Cash Flow	3,110	4,855	4,862	1,214	2,832
Operating Cash Flow Growth	-35.94%	-0.14%	300.49%	-57.13%	-24.30%
Capital Expenditures	-1,065	-1,185	-1,043	-634	-281
Investment in Securities	1,993	-12	639	2,751	-2,186
Other Investing Activities	299	337	253	187	218
Investing Cash Flow	1,227	-860	-151	2,304	-2,249
Long-Term Debt Repaid	-178	-175	-165	-153	-112
Net Debt Issued (Repaid)	-178	-175	-165	-153	-112
Common Dividends Paid	-4,326	-4,099	-2,732	-3,188	-1,548
Other Financing Activities	-91	-120	-120	-118	-77
Financing Cash Flow	-4,595	-4,394	-3,017	-3,459	-1,737
Foreign Exchange Rate Adjustments	3	-11	3	-	-
Net Cash Flow	-255	-410	1,697	59	-1,154
Free Cash Flow	2,045	3,670	3,819	580	2,551
Free Cash Flow Growth	-44.28%	-3.90%	558.45%	-77.26%	-21.82%
Free Cash Flow Margin	5.00%	9.26%	10.04%	1.84%	10.54%
Free Cash Flow Per Share	44.91	80.59	83.86	12.74	56.02
Cash Interest Paid	91	120	120	118	77
Cash Income Tax Paid	1,654	1,708	1,425	1,132	820
Levered Free Cash Flow	429	3,783	3,283	249.38	5,527
Unlevered Free Cash Flow	485.88	3,844	3,345	305.63	5,578
Change in Net Working Capital	2,828	-727	-749	2,080	-3,388

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.